🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4396 Illinois 2477 Georgia 2346 Arizona 2230
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca173 Eli Lilly and Company150 Merck Sharp & Dohme LLC116 AbbVie112 Novartis Pharmaceuticals107
State
California5299 Florida4396 Illinois2477 Georgia2346 Arizona2230
All 51 states
Target enrolment
to

Trials with a site in Florida

4396 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
NCT06725030Open Surgery, Lymphedema, Free Tissue Transfer, Microsurgery
MMI (Medical Microinstruments, Inc.)
Observational
455
California, Connecticut, Florida, New York, Ohio
2025-09-22
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Alnylam Pharmaceuticals
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-09-22
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-09-17
Recruiting
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Recruiting
Night Owl Sleep Study: The Effect of Sleep on Fecal Microbiota
NCT07243574Sleep
Danisco
Not applicable
174
Florida, Massachusetts, New York
2025-09-17
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
NCT07228026Asthma
Biometry Inc
Observational
160
California, Florida, Georgia, Maine, Maryland, Nebraska, North Carolina, Ohio
2025-09-17
Recruiting
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
NCT07104162Bacterial Infections
Qpex Biopharma, Inc.
Phase 1
40
Florida
2025-09-16
Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758Extensive Stage Small Cell Lung Cancer
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
NCT07207707Solid Tumor Malignancies
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2025-09-16
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Phase 3
160
Alabama, California, Colorado, District of Columbia, Florida, Louisiana, Pennsylvania, Tennessee
2025-09-16
Recruiting
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
NCT06052254Agitation
Teikoku Pharma USA, Inc.
Phase 2
150
California, Florida, Massachusetts, New Jersey
2025-09-16
Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161Hypertension, Uncontrolled Hypertension
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
By invitation
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
NCT07480343Open-angle Glaucoma (OAG)
Iantrek, Inc.
Observational
250
California, Florida, Georgia, Maryland, Nevada, Pennsylvania, Tennessee, Utah
2025-09-15
Recruiting
Data Collection Using Eko Digital Devices in a Clinical Setting
NCT07227376Lung Diseases
Eko Devices, Inc.
Observational
250
Florida, Pennsylvania
2025-09-14
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-09-13
Recruiting
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
NCT07020819Guillain-Barre Syndrome
Annexon, Inc.
Phase 3
30
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-09-12
Recruiting
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Louisiana
2025-09-11
Active, closed
An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
NCT06894511Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Phase 2
7
Arizona, California, Florida, Nebraska
2025-09-11
Recruiting
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
NCT07207408Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Dynavax Technologies Corporation
Phase 2
148
Florida, Kansas, Nevada, Ohio
2025-09-11
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
NCT06784466Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF
Arga Medtech SA
Not applicable
360
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2025-09-10
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828Severe Alopecia Areata
Pfizer
Phase 3
140
California, Florida, Indiana, Maryland, Michigan, Nebraska, New Mexico, New York
2025-09-10
Active, closed
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics
Phase 2
10
Florida, North Carolina, Ohio, Oregon, Texas
2025-09-10
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
NCT06982508Antioxidant Absorption
NewAmsterdam Pharma
Phase 2
100
Florida
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-09-08
Recruiting
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
NCT07060716Kidney Transplant Rejection, Cell-free DNA
Insight Molecular Diagnostics
Observational
125
California, Florida, Ohio, Pennsylvania, Tennessee, Texas, Utah
2025-09-08
Recruiting
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
NCT06726161Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.
Phase 1/2
590
Alabama, Arizona, California, Florida, Kentucky, Maryland, Minnesota, Nebraska
2025-09-05
Active, closed
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
NCT07128615Influenza A
AstraZeneca
Phase 1/2
405
California, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada
2025-09-04
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Iowa
2025-09-04
Recruiting
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288Schizophrenia
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
Recruiting
Post-Approval Study of the Neuspera Sacral Neuromodulation System
NCT07144813Urinary Urgency Incontinence
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707Obesity
MBX Biosciences
Phase 1
124
Florida, Kentucky, Missouri, Tennessee
2025-09-03
Recruiting
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
NCT06919354Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
GentiBio, Inc
Phase 1
16
California, Florida, Massachusetts, New York, North Carolina
2025-09-03
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Recruiting
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
NCT07140783Vision Loss Night, Vision Disorders
Ocuphire Pharma, Inc.
Phase 3
580
Arizona, California, Florida, Illinois, Kansas, Massachusetts, North Carolina, Pennsylvania
2025-09-02
By invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289Colorectal Cancer
AbbVie
Phase 2
140
Alabama, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Recruiting
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Neurocrine Biosciences
Phase 4
100
Arkansas, California, Florida, Georgia, Illinois, Nebraska, Ohio, Texas
2025-08-29
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Florida
2025-08-28
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Florida, Iowa, Louisiana, Michigan, New York, Ohio, South Dakota, Texas
2025-08-28
Active, closed
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
NCT07120945Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis
Medtronic - MITG
Not applicable
70
Florida, North Carolina, Pennsylvania, Washington
2025-08-28
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
Phase 3
351
Arizona, California, Colorado, Florida, Illinois, Kansas, Maine, Missouri
2025-08-27
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.
Phase 2
150
Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2025-08-27
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
Merz North America, Inc.
Phase 3
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-08-27
Recruiting
A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers
NCT07159282Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU
Applied Biologics, LLC
Phase 4
60
Florida
2025-08-26
Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
NCT06977724Dry Eye Syndrome, Systemic Lupus Erythematosus
AbbVie
Phase 1
36
Florida, Illinois, Tennessee, Texas
2025-08-26
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Active, closed
A Study Evaluating TRIV-509 in Atopic Dermatitis
NCT07167758Atopic Dermatitis
Triveni Bio
Phase 2
95
California, Florida, Indiana, Pennsylvania, Texas, Washington
2025-08-26
Active, closed
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
NCT07150845Atoptic Dermatitis
Evommune, Inc.
Phase 2
120
Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan, Missouri
2025-08-26
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
Basilea Pharmaceutica
Phase 3
234
Alabama, California, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota
2025-08-26
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07160244Healthy
Pfizer
Phase 3
6,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Louisiana, Maryland
2025-08-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Florida, Tennessee, Texas
2025-08-25
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, Massachusetts, New York, Texas
2025-08-25
Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012Cardiovascular Disease
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx
Phase 3
218
Alabama, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland
2025-08-22
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Recruiting
Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System
NCT07287176Thyroid Nodule, Thyroid Goiter, Ablation
Pulse Biosciences, Inc.
Not applicable
100
Florida, New York
2025-08-21
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700Episodic Migraine
Merz Therapeutics GmbH
Phase 3
990
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
NCT07144111Hepatic Impairment
Genentech, Inc.
Phase 1
32
California, Florida, Texas
2025-08-21
Active, closed
A Study of SPY072 in Rheumatic Disease
NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
Spyre Therapeutics, Inc.
Phase 2
285
Arizona, California, Florida, Illinois, Maryland, Pennsylvania, Texas
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713Chronic Migraine
Merz Therapeutics GmbH
Phase 3
780
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
Phase 3
180
California, District of Columbia, Florida, Idaho, Louisiana, Massachusetts, Minnesota, New York
2025-08-21
Recruiting
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT06998407HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
Active, closed
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 2
240
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Montana
2025-08-19
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
218
Alabama, California, Florida, Illinois, Louisiana, New Mexico, Ohio, South Carolina
2025-08-19
Recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
338
California, Florida, Illinois, Indiana, Louisiana, Missouri, New York, Pennsylvania
2025-08-18
Recruiting
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501Major Depressive Disorder
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, Minnesota
2025-08-18
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485Non Small Cell Lung Cancer
Wayshine Biopharm, Inc.
Phase 2
40
California, Florida, Michigan, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2025-08-18
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
Florida, Michigan, Oregon, Texas, Utah, Virginia, Washington
2025-08-18
Recruiting
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
NCT06995482Healthy Postmenopausal Women
Kashiv BioSciences, LLC
Phase 1
40
Florida
2025-08-18
Recruiting
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103Solid Tumors
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
NCT07049328Alopecia Areata(AA)
HCW Biologics
Phase 1
30
Florida, Indiana, Ohio
2025-08-16
Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Nevada, New Jersey, Ohio
2025-08-15
Recruiting
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709Alzheimer's Disease
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
NCT07209475Diabetic Foot Ulcer (DFU), Amnio-Maxx
Royal Biologics
Phase 4
248
California, Florida, Georgia, Nebraska, New York, Oklahoma, Texas
2025-08-14
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio
2025-08-12
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
Sanofi
Phase 3
192
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-08-12
Recruiting
A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages
NCT07342400Cheek Wrinkles, Menopausal Women
Galderma R&D
Not applicable
40
Florida, New York
2025-08-12
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York
2025-08-12
Active, closed
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
NCT06985147Polycythemia Vera (PV)
Disc Medicine, Inc
Phase 2
60
Arizona, California, Florida, Minnesota, Missouri, North Carolina, Ohio, Oregon
2025-08-12
Recruiting
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618Prurigo Nodularis
Galderma R&D
Observational
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-08-11
Recruiting
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
NCT06628128Phenylketonuria (PKU)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
240
Florida, Oregon, Pennsylvania, Texas, Utah
2025-08-11
Recruiting
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
NCT07122986Healthy Participants
Pfizer
Phase 1
310
California, Florida, New York, Ohio, Tennessee
2025-08-11
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-08-11
Rows per page Showing 1101–1200 of 4396
Previous 10 11 12 13 14 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/florida?page=12

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4,396 of those studies with a site in Florida.

How many clinical trials are recruiting in Florida?

2,360 of the 4,396 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 103 have not yet opened recruitment, 1,824 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.